

Press Release

Zug, 2 June 2010

HBM BioVentures delegates the execution of the share buy-back programme to Bank Sarasin/NZB to avoid interruptions

As part of the buy-back programme that was approved at its ordinary shareholders' meeting on 4 September 2009, HBM BioVentures Ltd has already repurchased around 510,000 of its own shares, with a view to their cancellation. A number of companies in HBM BioVentures' portfolio are working on transactions that could be price-sensitive for HBM BioVentures. If such information is not communicated immediately, HBM BioVentures is prohibited from repurchasing any more of its own shares until the transactions are disclosed. To avoid interrupting the share buy-back programme, the Board of Directors of HBM BioVentures Ltd has decided to delegate its execution to Bank Sarasin & Co. Ltd/NZB Neue Zürcher Bank Ltd. This delegation has been approved by the Swiss Takeover Board. It allows HBM BioVentures to make adjustments to the buy-back plan on a monthly basis and to interrupt the programme at any time.

For further information, please contact Dr. Joachim Rudolf, CFO HBM BioVentures Ltd, tel.: +41 41 768 11 08, joachim.rudolf@hbmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures invests world-wide in some 35 mature young companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies. Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel: +41 41 768 11 08
Fax: +41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com